Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis Aims: Intraoperative consultation using frozen sections (FSs) is an integral component of clinical practice. As a quality control measure, FS diagnosis is subsequently compared with the findings on a FS control slide. These control slides can be used for immunohistochemistry, and the immunohistochemical performance in FS controls is known to be antibody-dependent. Isocitrate dehydrogenase (IDH) is mutated in >80% of lower-grade infiltrating gliomas in adults and in~10% of glioblastomas, with IDH1 (R132H) being the most common mutation. IDH status is used as a major classifier of glioma. An IDH1 (R132H)-specific antibody (H09) has been accepted as a robust surrogate for genetic testing. In this study, we aimed to determine how previous freezing and thawing affects IDH1 immunohistochemistry. Methods and results: Thirty cases of IDH1 (R132H)-mutant diffuse glioma, which were originally assessed on FSs, were retrieved. The positive IDH1 (R132H) status of each case was previously determined with pyrosequencing and H09 immunohistochemistry on permanent sections. The FS control tissue of each case was immunostained with H09 antibody. Among 30 gliomas, 25 showed negative reactivity on FS control slides, whereas, in the remaining five, the staining was uninterpretable, owing to a high diffuse background. Of the former 25 specimens, 20 showed at least focal areas with variably increased levels of background staining, whereas the remaining five specimens showed a relatively pristine background. Conclusions: We conclude that IDH1 (R132H)-specific (H09) immunohistochemistry often results in falsenegative reactions on FS controls with focally increased background staining, and this application should be avoided in clinical practice.
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Introduction
Intraoperative consultation using frozen sections (FSs) is an integral component of diagnostic practice. As a quality control measure, FS diagnosis is subsequently compared with the findings on an FS control slide, which is prepared after thawing and fixing of the actual FS tissue. Although these control slides are typically not subjected to further assays, in some cases they may be used for immunohistochemistry. 1 For example, at our institution, among the 2037 cases that received an FS diagnosis in 2017, immunohistochemical staining was performed on FS control slides in 116 cases (5.7%), with the most common example being cytokeratin staining of lymph nodes that were morphologically equivocal for metastasis on FSs. The immunohistochemical performance on FS control slides is known to be antibody-dependent. A previous study demonstrated that antibodies against some proteins (such as cytokeratin or glial fibrillary acidic protein) have comparable performance to that on standard sections, whereas those against other proteins, such as S100 protein, can be severely affected by previous freezing and thawing. 1 Isocitrate dehydrogenase (IDH) is mutated in >80% of lower-grade infiltrating gliomas in adults and iñ 10% of glioblastomas, with the IDH1 (R132H) mutation being the most common (>80%).
2 IDH mutation status is used as a major classifier of glioma in the present World Health Organization scheme, with high prognostic significance, and is necessary for an integrated diagnosis to be conferred.
2,3 IDH status can also be of diagnostic help, because the mutation is limited to infiltrating gliomas, and is not seen in gliosis or localised gliomas. [4] [5] [6] [7] Although IDH mutation status can be determined with sequencing or other DNA-based methods, an IDH1 (R132H)-specific antibody (clone H09; Dianova, Hamburg, Germany) has been accepted as a robust surrogate and is used widely, as its accuracy is considered to be equivalent to that of sequencing. 6 When tumour content is low in specimens, immunohistochemistry can outperform sequencing, because the antibody labels mutant samples at single-cell resolution. 4, 8 Having routinely used this reagent over years, we have also found it to be a reliable tool that provides nearly perfect concordance with the sequencing results that are obtained in parallel. However, we have recently encountered a case of genetically proven IDH1 (R132H)-mutant diffuse glioma whose specimen was submitted by an outside institution and showed negative results on H09 immunohistochemistry. Knowing that this tissue was an FS control, we aimed to determine how previous freezing and thawing affects IDH1 immunohistochemistry.
Materials and methods

C A S E S
After approval from the institutional review board had been obtained (2013-042), 30 in-house cases of IDH1 (R132H)-mutant diffuse glioma were retrieved from the archive of the Department of Pathology, National Cancer Centre Hospital, Tokyo, Japan (2011-2016). These 30 cases were selected because all of them had previously been assessed on intraoperative FSs, and the corresponding FS control slides contained an adequate number of tumour cells. They were two diffuse astrocytomas, four oligodendrogliomas, four oligoastrocytomas, eight anaplastic astrocytomas, two anaplastic oligoastrocytomas, and 10 glioblastomas, on the basis of the original pathology reports. The positive IDH1 (R132H) status of each case had previously been determined with H09 immunohistochemistry on permanent (not previously frozen) sections. Furthermore, in all cases, the presence of the mutation was also confirmed by pyrosequencing with our validated method, which has been described previously.
I M M U N O H I S T O C H E M I S T R Y
A 4-lm-thick section freshly cut from the FS control block of each tumour was deparaffinised. The sections were exposed to 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity, and then washed with deionized water for 2-3 min. The preparations were autoclaved in citrate buffer (pH 6.0) for antigen retrieval. Slides were incubated for 1 h at room temperature with the primary antibody (H09, dilution 1:50), and subsequently labelled by use of the EnVision system with LINKER (Dako, Glostrup, Denmark). Diaminobenzidine was used as the chromogen, and haematoxylin as the counterstain. 8 Distinct cytoplasmic signals with or without nuclear staining in the tumour cells were considered to indicate positivity, as previously recommended by a guideline, 6 and any other colouration not meeting these criteria was regarded as background staining. This staining and interpretation method has been internally validated and is in routine use at our institution.
F S P R O T O C O L
Our FS method involved tissue embedding in optimal cutting temperature compound (Sakura Finetek, Tokyo, Japan) and rapid freezing in a dry ice/acetone cooling bath (À78°C). After being sectioned in a cryostat for diagnosis, frozen tissues were allowed to thaw at room temperature, fixed in 10% formalin, and routinely prepared to make a control slide.
Results
Among the 30 diffuse gliomas, 25 showed negative H09 reactivity on FS control slides (Figures 1 and 2) , whereas, in the remaining five, the staining was uninterpretable, owing to a high diffuse background. Of the former 25 specimens, 20 showed focal areas with variably increased levels of background staining, whereas the remaining five cases showed a relatively pristine background. Background staining was always blurry and without the distinct cytoplasmic quality required for it to be interpreted as positive, and decorated both neoplastic and non-neoplastic elements (e.g. endothelial cells).
Discussion
Because the IDH1 (R132H) mutation is an early driver of gliomagenesis, 2 and is therefore present in almost all tumour cells, 6 our observations of discordant staining are best interpreted as false negativity on FS control slides. There were probably technical reasons for this; perhaps there was leakage and diffusion of the antigen from tumour cells because of the damage to the membranes caused by freezing and thawing. 1 Increased background staining, which was focally or diffusely observed in most of our cases, might be related to leakage of mutant IDH1 protein; however, we have observed similarly increased background staining when using the same antibody on FS control slides of some gliomas with wild-type IDH, so this could be merely a non-specific artefact.
Given the significant clinical and diagnostic implications of IDH status in neuro-oncology, this false negativity could be a potential pitfall. This is most relevant when minute stereotactic biopsy specimens are inadvertently submitted in toto for FS diagnosis, with permanent sections containing only non-diagnostic material. Caution should also be exercised when one tries to identify IDH1-mutant glioma cells in a specimen that had been interpreted as equivocal for tumour involvement on an FS. Although most glioma specimens that are immunonegative for IDH1 (R132H) should be further tested with sequencing to avoid missing other types of IDH1 or IDH2 mutation, in some situations (e.g. glioblastoma in patients aged >55 years without a prior history of lower-grade glioma) IDH status may be determined solely on the basis of immunohistochemistry data for practical purposes.
2 IDH1 (R132H) staining has no internal positive control in non-neoplastic brain tissues, and this false-negative reaction must be difficult for the unwary to notice, except for at least the focal presence of a variably increased level of background staining in most cases.
This single-institution study cannot answer the question of whether our own freezing-thawing method specifically diminishes immunoreactivity, and whether modification of the method may allow this pitfall to be avoided. However, this false negativity seems to be reproducible across institutions, given that our index case was a referral, with the corresponding FS being prepared at an outside hospital. Additionally, in an earlier study that analysed 10 IDH1 (R132H)-mutant diffuse astrocytomas, the only specimen that was previously frozen showed 'only rare positive' cells, in contrast to diffuse strong reactivity in all the other cases, 9 and that case was, in fact, once reported as immunonegative on the basis of the initial staining. 5 The authors of the article rightly suspected that neuropathologists may need to select previously unfrozen tissue for mutant IDH1 immunohistochemistry. 9 In conclusion, IDH1 (R132H)-specific immunohistochemistry (H09) often results in false-negative reactions on FS control slides, and this application should be avoided in clinical practice. Negative IDH1 staining results need to be carefully interpreted, particularly for cases in referral settings, when the tissue-processing history may be unclear.
